Cited 2 times in
Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경민 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 황상현 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 김동우 | - |
dc.date.accessioned | 2022-12-22T02:20:48Z | - |
dc.date.available | 2022-12-22T02:20:48Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 0363-9762 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191538 | - |
dc.description.abstract | Purpose: This study aimed to evaluate the prognostic value of metabolic parameters on 18F-FDG PET/CT and tumor dose (TD) on posttreatment 90Y PET/CT in patients with hepatocellular carcinoma (HCC) who underwent 90Y transarterial radioembolization (TARE). Patients and methods: Forty-seven HCC patients treated with 90Y TARE were retrospectively enrolled between January 2013 and October 2018. 18F-FDG PET/CT was performed before treatment. Maximum tumor SUV-to-mean normal liver SUV ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for each patient. Voxel dosimetry was performed on 90Y PET/CT images to measure TD. The prognostic significance of metabolic parameters on 18F-FDG PET/CT, TD on 90Y PET/CT, and clinical factors for overall survival (OS) was evaluated. In addition, TD on 90Y PET/CT was analyzed in relation to the administered dose of 90Y-labeled microspheres and metabolic parameters on 18F-FDG PET/CT. Results: The median patient age was 57 years, and 37 patients (78.7%) were men. During the follow-up period, 25 patients (53.2%) died. In univariable analysis, Barcelona Clinic Liver Cancer stage C, Child-Pugh score, TD on 90Y PET/CT, TLR, MTV, and TLG were significant prognostic factors affecting OS (P < 0.05). In multivariable analysis, Barcelona Clinic Liver Cancer stage C and high TLG on 18F-FDG PET/CT were independent prognostic factors for OS (P < 0.05). The 1-year OS rates were 72.9% in patients with low TLG and 33.3% in patients with high TLG (P < 0.05). We also found that TD on 90Y PET/CT was not correlated with the administered dose of 90Y-labeled microspheres, but negatively correlated with TLG on pretreatment 18F-FDG PET/CT (P < 0.05). Conclusions: TLG, a parameter incorporating both the degree of 18F-FDG uptake and amount of metabolically active tumor volume on pretreatment 18F-FDG PET/CT, is a better prognostic factor than TD on 90Y PET/CT for predicting OS in HCC patients treated with 90Y TARE. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott | - |
dc.relation.isPartOf | CLINICAL NUCLEAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / diagnostic imaging | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18 / metabolism | - |
dc.subject.MESH | Glycolysis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms* / diagnostic imaging | - |
dc.subject.MESH | Liver Neoplasms* / metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Tumor Burden | - |
dc.subject.MESH | Yttrium Radioisotopes / therapeutic use | - |
dc.title | Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학교실) | - |
dc.contributor.googleauthor | Sang Hyun Hwang | - |
dc.contributor.googleauthor | Hye-Suk Hong | - |
dc.contributor.googleauthor | Dongwoo Kim | - |
dc.contributor.googleauthor | Gyoung Min Kim | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Misu Lee | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Mi-Ae Park | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1097/RLU.0000000000004128 | - |
dc.contributor.localId | A00296 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A05953 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J00595 | - |
dc.identifier.eissn | 1536-0229 | - |
dc.identifier.pmid | 35384891 | - |
dc.identifier.url | https://journals.lww.com/nuclearmed/Fulltext/2022/06000/Total_Lesion_Glycolysis_on_18F_FDG_PET_CT_Is_a.26.aspx | - |
dc.contributor.alternativeName | Kim, Gyoung Min | - |
dc.contributor.affiliatedAuthor | 김경민 | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 황상현 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 47 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | E437 | - |
dc.citation.endPage | E443 | - |
dc.identifier.bibliographicCitation | CLINICAL NUCLEAR MEDICINE, Vol.47(6) : E437-E443, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.